Company registration number SC190022 (Scotland)
RENAISSANCE CARE (SCOTLAND) LIMITED
ANNUAL REPORT AND FINANCIAL STATEMENTS
FOR THE YEAR ENDED 30 NOVEMBER 2025
RENAISSANCE CARE (SCOTLAND) LIMITED
COMPANY INFORMATION
Directors
Mr R D Kilgour
Mr R D Harper
Mrs A Neilson
Mrs L Barnett
Mrs Y Richardson
Mr M H Reid
Mr L M Bain
Ms K Feenan
(Appointed 17 June 2025)
Company number
SC190022
Registered office
Archibald Hope House
Station Road
Musselburgh
Scotland
EH21 7PQ
Auditor
Thomson Cooper
3 Castle Court
Carnegie Campus
Dunfermline
Fife
KY11 8PB
Bankers
Barclays Bank (Canary Wharf)
1 Churchill Place
Canary Wharf
London
E14 5HP
Solicitors
Morton Fraser MacRoberts LLP
Level 5
9 Haymarket Square
Edinburgh
EH3 8RY
RENAISSANCE CARE (SCOTLAND) LIMITED
CONTENTS
Page
Strategic report
1 - 2
Directors' report
3 - 5
Independent auditor's report
6 - 8
Group statement of comprehensive income
9
Group statement of financial position
10
Company statement of financial position
11
Group statement of changes in equity
12
Company statement of changes in equity
13
Group statement of cash flows
14
Company statement of cash flows
15
Notes to the financial statements
16 - 34
RENAISSANCE CARE (SCOTLAND) LIMITED
STRATEGIC REPORT
FOR THE YEAR ENDED 30 NOVEMBER 2025
- 1 -

The directors present the strategic report for the year ended 30 November 2025.

Activities of the Group

The principal activity of the Group during the year was the operation of care homes for the elderly.

 

The Group pays its care staff the 'Scottish Living Wage' while all other staff are paid at or above the 'National Living Wage'. These nationally prescribed rates fall to be reviewed in April each year. This year our gender pay gap, on the mean pay gap measure, was in favour of women at 4.6% (2024: 6.6% in favour of women). The gap using the median measure is 1.1% in favour of men (2024: 2.8% in favour of women). The group predominately employs women, with men forming around 21% of the staff. This means that a modest change in the mix of senior staff has a disproportionate effect on the pay gap. The Group continues to offer all roles at the same rate of pay to both men and women.

 

The Group continued to perform strongly throughout the year, demonstrating operational resilience and delivering high quality care across the portfolio, despite a challenging operating environment. Occupancy levels improved, with average occupancy for the year at just over 94%. The Group was delighted to welcome Cranford Care Home to the family in February 2025, adding to the group’s cluster of homes in Aberdeen. The Directors continue to look at opportunities to grow the Group, and were delighted to welcome Berelands Care Home in Prestwick to the Group in December 2025.

 

The Group continues to embrace technology, particularly where it enhances the quality of care for residents. With all our homes now utilising electronic care planning, we have now embarked on the roll out of electronic Medication Administration Records (eMAR) and pain management tools to further support our staff in delivering high quality care to our residents.

 

The Group continues to invest significantly in the portfolio to make our homes the best they can be for our residents and staff, whilst striving to reduce their environmental impact.

 

Financial Performance

 

The Directors are pleased to report improved financial performance for the group for this year. Turnover for the group increased by 15% to £52,518,142. The operating profit of the group for the year was £2,224,068 which is up on the previous financial year which was £1,980,653. At the balance sheet date, the group had reserves of £4,001,364 (2024 - £2,458,955). The group did not make any dividend payments to the ultimate parent company during the year (2024: Nil).

Employment

The Group looks to recruit, develop and employ throughout the organisation appropriately qualified, capable and experienced staff irrespective of race, religion or sexual orientation. Full consideration is given to applications from disabled persons - looking to their particular aptitudes and abilities. Equally, any employee becoming disabled during their employment will be assessed for their suitability for continued employment and offered retraining or redeployment as required.

 

The Group communicates with its staff in staff meetings, by letter and through its regular staff newsletter. Increasingly email and social media channels have been used to good effect.

 

All employees are encouraged in terms of their career development and the Group generally supports those who undertake further qualifications. The Group continues to train its senior care staff to undertake many of the tasks normally regarded as the responsibility of trained nurses. Subject to Care Inspectorate approval, deployment of these staff members helps controls costs and reduces reliance on nurses.

 

Supplier Payment Policy

The Group's policy is to pay suppliers in a timely manner. The Group clearly understands that the maintenance of a reliable payment pattern is important to suppliers and that suppliers' support is fundamental to the success of the business.

 

RENAISSANCE CARE (SCOTLAND) LIMITED
STRATEGIC REPORT (CONTINUED)
FOR THE YEAR ENDED 30 NOVEMBER 2025
- 2 -
Key Performance Indicators
2025
2024
Care Inspection Scores (Average)
4.3
4.0
£
£
Turnover
52,518,142
45,846,412
EBITDAR
9,021,370
8,108,765

Care Inspection Quality Ratings; the average Care Inspection score achieved across all homes. Homes are rated out of 6 (2 being Weak, 4 being Good and 6 being Excellent).

 

Average Occupancy; the percentage of registered beds occupied, on average, over the year.

 

Turnover; total sales achieved.

 

EBITDAR; earnings before Interest, Tax, Depreciation, Amortisation and Rent.

 

The Board are encouraged that the Group has continued to trade profitably and expects it to do so during the next accounting period.

Principal Risks and Uncertainties

Renaissance Care (Scotland) Limited, like any business, faces a number of operating risks and uncertainties that could impact the Group's performance. Steps are taken to understand and evaluate these risks and to mitigate against them in order to achieve the Directors' long term goal of creating a sustainable business which delivers benefits to all stakeholders. The most fundamental risks faced by the Group are:

 

Failure to:

 

Rising costs also pose a significant risk. Both short term and long term forecasts have been modelled to confirm our stability and we are closely monitoring operations and the financial impact on our business.

On behalf of the board

Mr L M Bain
Director
28 May 2026
RENAISSANCE CARE (SCOTLAND) LIMITED
DIRECTORS' REPORT
FOR THE YEAR ENDED 30 NOVEMBER 2025
- 3 -

The directors present their annual report and financial statements for the year ended 30 November 2025.

Principal activities

The principal activity of the company and group continued to be that of the operation of care homes for the elderly.

Results and dividends

The results for the year are set out on page 9.

Ordinary dividends were paid amounting to £40,000. The directors do not recommend payment of a further dividend.

Directors

The directors who held office during the year and up to the date of signature of the financial statements were as follows:

Mr R D Kilgour
Mr R D Harper
Mrs A Neilson
Mrs L Barnett
Mrs Y Richardson
Mr M H Reid
Mr L M Bain
Ms K Feenan
(Appointed 17 June 2025)
Directors' share options

Details of directors' share options in Renaissance Care (Scotland) Limited are as follows:

At 1 December 2024
Granted
Exercised
At 30 November 2025
Exercise date
Date from which exercisable
Expiry  date
Liam Bain
2,924
2,924
01/10/2023
01/10/2028
Disabled persons

Applications for employment by disabled persons are always fully considered, bearing in mind the aptitudes of the applicant concerned. In the event of members of staff becoming disabled, every effort is made to ensure that their employment within the group continues and that the appropriate training is arranged. It is the policy of the group that the training, career development and promotion of disabled persons should, as far as possible, be identical to that of other employees.

Employee involvement

The group's policy is to consult and discuss with employees, through unions, staff councils and at meetings, matters likely to affect employees' interests.

 

Information about matters of concern to employees is given through information bulletins and reports which seek to achieve a common awareness on the part of all employees of the financial and economic factors affecting the group's performance.

 

There is no employee share scheme at present, but the directors are considering the introduction of such a scheme as a means of further encouraging the involvement of employees in the company's performance.

Auditor

The auditor, Thomson Cooper, is deemed to be reappointed under section 487(2) of the Companies Act 2006.

RENAISSANCE CARE (SCOTLAND) LIMITED
DIRECTORS' REPORT (CONTINUED)
FOR THE YEAR ENDED 30 NOVEMBER 2025
- 4 -
Energy and carbon report
2025
2024
Energy consumption
kWh
kWh
Aggregate of energy consumption in the year
- Gas combustion
7,322,249
6,996,844
- Electricity purchased
3,437,100
3,457,973
- Fuel consumed for transport
271,271
220,406
11,030,620
10,675,223
2025
2024
Emissions of CO2 equivalent
metric tonnes
metric tonnes
Scope 1 - direct emissions
- Gas combustion
1,432.00
1,348.00
- Fuel consumed for owned transport
67.00
54.00
1,499.00
1,402.00
Scope 2 - indirect emissions
- Electricity purchased
672.00
779.00
Scope 3 - other indirect emissions
- Fuel consumed for transport not owned by the group
107.00
137.00
Total gross emissions
2,278.00
2,318.00
Intensity ratio
teCO2 per £m of turnover
48.37
49.23
Quantification and reporting methodology

The group has followed the 2019 HM Government Environmental Reporting Guidelines. The group has also used the GHG Reporting Protocol – Corporate Standard and have used the 2020 UK Government’s Conversion Factors for Company Reporting.

Intensity measurement

The reporting intensity ratio used is tonnes of CO2 per £m turnover. It is considered that this provides the best representation of the activities of the company and comparison throughout the industry.

Measures taken to improve energy efficiency

During the year we continued our programme to replace conventional lighting with LED. We recycle over 90% of our total waste and are constantly looking at ways to improve this statistic. We continue to look at ways to reduce our carbon footprint.

RENAISSANCE CARE (SCOTLAND) LIMITED
DIRECTORS' REPORT (CONTINUED)
FOR THE YEAR ENDED 30 NOVEMBER 2025
- 5 -
Statement of directors' responsibilities

The directors are responsible for preparing the Annual Report and the financial statements in accordance with applicable law and regulations.

 

Company law requires the directors to prepare financial statements for each financial year. Under that law, the directors have prepared the group and parent company financial statements in accordance with United Kingdom Generally Accepted Accounting Practice (United Kingdom Accounting Standards and applicable law). Under company law, the directors must not approve the financial statements unless they are satisfied that they give a true and fair view of the state of affairs of the group and parent company, and of the profit or loss of the group for that period.

 

In preparing these financial statements, the directors are required to:

 

The directors are responsible for keeping adequate accounting records that are sufficient to show and explain the group’s and parent company’s transactions and disclose with reasonable accuracy at any time the financial position of the group and parent company, and enable them to ensure that the financial statements comply with the Companies Act 2006. They are also responsible for safeguarding the assets of the group and parent company, and hence for taking reasonable steps for the prevention and detection of fraud and other irregularities.

Statement of disclosure to auditor

So far as each person who was a director at the date of approving this report is aware, there is no relevant audit information of which the auditor of the company is unaware. Additionally, the directors individually have taken all the necessary steps that they ought to have taken as directors in order to make themselves aware of all relevant audit information and to establish that the auditor of the company is aware of that information.

Disclosure of information in the strategic report

The group has chosen in accordance with section 414C(11) of the Companies Act 2006 (Strategic Report and Directors' Report) Regulations 2013 to set out in the group's strategic report information required by schedule 7 of the Large and Medium-sized Companies and Groups (Accounts and Reports) Regulations 2008.

On behalf of the board
Mr L M Bain
Director
28 May 2026
RENAISSANCE CARE (SCOTLAND) LIMITED
INDEPENDENT AUDITOR'S REPORT
TO THE MEMBERS OF RENAISSANCE CARE (SCOTLAND) LIMITED
- 6 -
Opinion

We have audited the financial statements of Renaissance Care (Scotland) Limited (the 'parent company') and its subsidiaries (the 'group') for the year ended 30 November 2025 which comprise the group statement of comprehensive income, the group statement of financial position, the company statement of financial position, the group statement of changes in equity, the company statement of changes in equity, the group statement of cash flows, the company statement of cash flows and notes to the financial statements, including significant accounting policies. The financial reporting framework that has been applied in their preparation is applicable law and United Kingdom Accounting Standards, including Financial Reporting Standard 102 The Financial Reporting Standard applicable in the UK and Republic of Ireland (United Kingdom Generally Accepted Accounting Practice).

In our opinion the financial statements:

Basis for opinion

We conducted our audit in accordance with International Standards on Auditing (UK) (ISAs (UK)) and applicable law. Our responsibilities under those standards are further described in the Auditor's responsibilities for the audit of the financial statements section of our report. We are independent of the group and parent company in accordance with the ethical requirements that are relevant to our audit of the financial statements in the UK, including the FRC’s Ethical Standard, and we have fulfilled our other ethical responsibilities in accordance with these requirements. We believe that the audit evidence we have obtained is sufficient and appropriate to provide a basis for our opinion.

Conclusions relating to going concern

In auditing the financial statements, we have concluded that the directors' use of the going concern basis of accounting in the preparation of the financial statements is appropriate.

 

Based on the work we have performed, we have not identified any material uncertainties relating to events or conditions that, individually or collectively, may cast significant doubt on the group's and parent company's ability to continue as a going concern for a period of at least twelve months from when the financial statements are authorised for issue.

 

Our responsibilities and the responsibilities of the directors with respect to going concern are described in the relevant sections of this report.

Other information

The other information comprises the information included in the annual report other than the financial statements and our auditor's report thereon. The directors are responsible for the other information contained within the annual report. Our opinion on the financial statements does not cover the other information and, except to the extent otherwise explicitly stated in our report, we do not express any form of assurance conclusion thereon. Our responsibility is to read the other information and, in doing so, consider whether the other information is materially inconsistent with the financial statements or our knowledge obtained in the course of the audit, or otherwise appears to be materially misstated. If we identify such material inconsistencies or apparent material misstatements, we are required to determine whether this gives rise to a material misstatement in the financial statements themselves. If, based on the work we have performed, we conclude that there is a material misstatement of this other information, we are required to report that fact.

 

We have nothing to report in this regard.

Opinions on other matters prescribed by the Companies Act 2006

In our opinion, based on the work undertaken in the course of our audit:

RENAISSANCE CARE (SCOTLAND) LIMITED
INDEPENDENT AUDITOR'S REPORT (CONTINUED)
TO THE MEMBERS OF RENAISSANCE CARE (SCOTLAND) LIMITED
- 7 -
Matters on which we are required to report by exception

In the light of the knowledge and understanding of the group and the parent company and their environment obtained in the course of the audit, we have not identified material misstatements in the strategic report or the directors' report.

 

We have nothing to report in respect of the following matters in relation to which the Companies Act 2006 requires us to report to you if, in our opinion:

Responsibilities of directors

As explained more fully in the directors' responsibilities statement, the directors are responsible for the preparation of the financial statements and for being satisfied that they give a true and fair view, and for such internal control as the directors determine is necessary to enable the preparation of financial statements that are free from material misstatement, whether due to fraud or error. In preparing the financial statements, the directors are responsible for assessing the group's and parent company's ability to continue as a going concern, disclosing, as applicable, matters related to going concern and using the going concern basis of accounting unless the directors either intend to liquidate the group or parent company or to cease operations, or have no realistic alternative but to do so.

Auditor's responsibilities for the audit of the financial statements

Our objectives are to obtain reasonable assurance about whether the financial statements as a whole are free from material misstatement, whether due to fraud or error, and to issue an auditor's report that includes our opinion. Reasonable assurance is a high level of assurance but is not a guarantee that an audit conducted in accordance with ISAs (UK) will always detect a material misstatement when it exists. Misstatements can arise from fraud or error and are considered material if, individually or in the aggregate, they could reasonably be expected to influence the economic decisions of users taken on the basis of these financial statements.

The extent to which our procedures are capable of detecting irregularities, including fraud, is detailed below.

Extent to which the audit was considered capable of detecting irregularities, including fraud

We considered the opportunities and incentives that may exist within the organisation for fraud and identified the greatest potential for fraud in the following areas: existence and timing of recognition of income, posting of unusual journals along with complex transactions and manipulating the Groups key performance indicators to meet targets. We discussed these risks with management, designed audit procedures to test the timing and existence of revenue, tested a sample of journals to confirm they were appropriate and reviewed areas of judgement for indicators of management bias to address these risks.

We identified areas of laws and regulations that could reasonably be expected to have a material effect on the financial statements from our sector experience and through discussion with the officers and other management (as required by the auditing standards).

We reviewed the laws and regulations in areas that directly affect the financial statements including financial and taxation legislation and Care Inspectorate regulations recognising the regulated nature of the company’s activities. We considered the extent of compliance with those laws and regulations as part of our procedures on the related financial statement items.

With the exception of any known or possible non-compliance with relevant and significant laws and regulations, and as required by the auditing standards, our work in respect of these was limited to enquiry of the officers and management of the group.

We communicated identified laws and regulations throughout our team and remained alert to any indications of non-compliance throughout the audit.

RENAISSANCE CARE (SCOTLAND) LIMITED
INDEPENDENT AUDITOR'S REPORT (CONTINUED)
TO THE MEMBERS OF RENAISSANCE CARE (SCOTLAND) LIMITED
- 8 -

Owing to the inherent limitations of an audit, there is an unavoidable risk that we may not have detected some material misstatements in the financial statements, even though we have properly planned and performed our audit in accordance with auditing standards. We are not responsible for preventing non-compliance and cannot be expected to detect non-compliance with all laws and regulations.

These inherent limitations are particularly significant in the case of misstatement resulting from fraud as this may involve sophisticated schemes designed to avoid detection, including deliberate failure to record transactions, collusion or the provision of intentional misrepresentations.

A further description of our responsibilities is available on the Financial Reporting Council’s website at: https://www.frc.org.uk/auditorsresponsibilities. This description forms part of our auditor's report.

Use of our report

This report is made solely to the parent company’s members, as a body, in accordance with Chapter 3 of Part 16 of the Companies Act 2006. Our audit work has been undertaken so that we might state to the parent company’s members those matters we are required to state to them in an auditor's report and for no other purpose. To the fullest extent permitted by law, we do not accept or assume responsibility to anyone other than the parent company and the parent company’s members as a body, for our audit work, for this report, or for the opinions we have formed.

Sharon Collins (Senior Statutory Auditor)
For and on behalf of Thomson Cooper, Statutory Auditor
Dunfermline
28 May 2026
RENAISSANCE CARE (SCOTLAND) LIMITED
GROUP STATEMENT OF COMPREHENSIVE INCOME
FOR THE YEAR ENDED 30 NOVEMBER 2025
- 9 -
2025
2024
Notes
£
£
Turnover
2
52,518,142
45,846,412
Cost of sales
(33,083,444)
(27,655,397)
Gross profit
19,434,698
18,191,015
Administrative expenses
(17,218,280)
(16,225,749)
Other operating income
7,650
15,387
Operating profit
3
2,224,068
1,980,653
Interest receivable and similar income
6
15,179
4,572
Interest payable and similar expenses
7
(80,753)
(3,626)
Profit before taxation
2,158,494
1,981,599
Tax on profit
8
(576,085)
(286,185)
Profit for the financial year
25
1,582,409
1,695,414
Profit for the financial year is all attributable to the owners of the parent company.
Total comprehensive income for the year is all attributable to the owners of the parent company.
RENAISSANCE CARE (SCOTLAND) LIMITED
GROUP STATEMENT OF FINANCIAL POSITION
AS AT
30 NOVEMBER 2025
30 November 2025
- 10 -
2025
2024
Notes
£
£
£
£
Fixed assets
Goodwill
10
1,623,153
1,321,221
Other intangible assets
10
32,479
44,896
Total intangible assets
1,655,632
1,366,117
Tangible assets
11
4,569,060
3,609,136
6,224,692
4,975,253
Current assets
Debtors
14
11,083,987
9,611,769
Cash at bank and in hand
3,035,693
2,165,493
14,119,680
11,777,262
Creditors: amounts falling due within one year
15
(14,525,608)
(13,623,676)
Net current liabilities
(405,928)
(1,846,414)
Total assets less current liabilities
5,818,764
3,128,839
Creditors: amounts falling due after more than one year
16
(906,000)
(17,888)
Provisions for liabilities
Deferred tax liability
19
858,056
598,652
(858,056)
(598,652)
Net assets
4,054,708
2,512,299
Capital and reserves
Called up share capital
22
52,632
52,632
Share premium account
23
263
263
Other reserves
449
449
Profit and loss reserves
25
4,001,364
2,458,955
Total equity
4,054,708
2,512,299
The financial statements were approved by the board of directors and authorised for issue on 28 May 2026 and are signed on its behalf by:
28 May 2026
Mr L M Bain
Director
Company registration number SC190022 (Scotland)
RENAISSANCE CARE (SCOTLAND) LIMITED
COMPANY STATEMENT OF FINANCIAL POSITION
AS AT 30 NOVEMBER 2025
30 November 2025
- 11 -
2025
2024
Notes
£
£
£
£
Fixed assets
Intangible assets
6,890
8,660
Tangible assets
11
2,514
3,815
Investments
12
1,875,495
2,001,343
1,884,899
2,013,818
Current assets
Debtors
14
5,231,084
4,384,021
Cash at bank and in hand
16,124
366,660
5,247,208
4,750,681
Creditors: amounts falling due within one year
15
(6,806,607)
(6,384,890)
Net current liabilities
(1,559,399)
(1,634,209)
Total assets less current liabilities
325,500
379,609
Provisions for liabilities
Deferred tax liability
19
629
954
(629)
(954)
Net assets
324,871
378,655
Capital and reserves
Called up share capital
22
52,632
52,632
Share premium account
23
263
263
Other reserves
449
449
Profit and loss reserves
25
271,527
325,311
Total equity
324,871
378,655

As permitted by section 408 of the Companies Act 2006, the company has not presented its own profit and loss account and related notes. The company’s loss for the year was £13,784 (2024 - £13,852 loss).

These financial statements have been prepared in accordance with the provisions applicable to companies subject to the small companies regime.

The financial statements were approved by the board of directors and authorised for issue on 28 May 2026 and are signed on its behalf by:
28 May 2026
Mr L M Bain
Director
Company registration number SC190022 (Scotland)
RENAISSANCE CARE (SCOTLAND) LIMITED
GROUP STATEMENT OF CHANGES IN EQUITY
FOR THE YEAR ENDED 30 NOVEMBER 2025
- 12 -
Share capital
Share premium account
Other reserves
Profit and loss reserves
Total
Notes
£
£
£
£
£
Balance at 1 December 2023
52,632
-
0
449
790,361
843,442
Year ended 30 November 2024:
Profit and total comprehensive income
-
-
-
1,695,414
1,695,414
Issue of share capital
22
-
0
263
-
-
263
Dividends
9
-
-
-
(26,820)
(26,820)
Balance at 30 November 2024
52,632
263
449
2,458,955
2,512,299
Year ended 30 November 2025:
Profit and total comprehensive income
-
-
-
1,582,409
1,582,409
Dividends
9
-
-
-
(40,000)
(40,000)
Balance at 30 November 2025
52,632
263
449
4,001,364
4,054,708
RENAISSANCE CARE (SCOTLAND) LIMITED
COMPANY STATEMENT OF CHANGES IN EQUITY
FOR THE YEAR ENDED 30 NOVEMBER 2025
- 13 -
Share capital
Share premium account
Other reserves
Profit and loss reserves
Total
Notes
£
£
£
£
£
Balance at 1 December 2023
52,632
-
0
449
365,983
419,064
Year ended 30 November 2024:
Loss and total comprehensive income for the year
-
-
-
(13,852)
(13,852)
Issue of share capital
22
-
0
263
-
-
263
Dividends
9
-
-
-
(26,820)
(26,820)
Balance at 30 November 2024
52,632
263
449
325,311
378,655
Year ended 30 November 2025:
Profit and total comprehensive income
-
-
-
(13,784)
(13,784)
Dividends
9
-
-
-
(40,000)
(40,000)
Balance at 30 November 2025
52,632
263
449
271,527
324,871
RENAISSANCE CARE (SCOTLAND) LIMITED
GROUP STATEMENT OF CASH FLOWS
FOR THE YEAR ENDED 30 NOVEMBER 2025
- 14 -
2025
2024
Notes
£
£
£
£
Cash flows from operating activities
Cash generated from operations
29
2,913,812
4,066,952
Interest paid
(80,753)
(3,626)
Income taxes paid
(295,074)
(224,116)
Net cash inflow from operating activities
2,537,985
3,839,210
Investing activities
Purchase of intangible assets
(483,968)
(1,357,457)
Proceeds from disposal of intangibles
8,340
-
Purchase of tangible fixed assets
(2,050,943)
(1,499,183)
Proceeds from disposal of tangible fixed assets
-
102,108
Interest received
15,179
4,572
Net cash used in investing activities
(2,511,392)
(2,749,960)
Financing activities
Proceeds from issue of shares
-
263
Drawdown of bank loans
906,000
-
Payment of finance leases obligations
(22,393)
(4,505)
Dividends paid to equity shareholders
(40,000)
(26,820)
Net cash generated from/(used in) financing activities
843,607
(31,062)
Net increase in cash and cash equivalents
870,200
1,058,188
Cash and cash equivalents at beginning of year
2,165,493
1,107,305
Cash and cash equivalents at end of year
3,035,693
2,165,493
RENAISSANCE CARE (SCOTLAND) LIMITED
COMPANY STATEMENT OF CASH FLOWS
FOR THE YEAR ENDED 30 NOVEMBER 2025
- 15 -
2025
2024
Notes
£
£
£
£
Cash flows from operating activities
Cash (absorbed by)/generated from operations
30
(434,397)
1,554,486
Interest paid
(2,292)
(2,500)
Net cash (outflow)/inflow from operating activities
(436,689)
1,551,986
Investing activities
Proceeds from disposal of subsidiaries
125,848
(1,281,056)
Interest received
305
-
0
Net cash generated from/(used in) investing activities
126,153
(1,281,056)
Financing activities
Proceeds from issue of shares
-
263
Dividends paid to equity shareholders
(40,000)
(26,820)
Net cash used in financing activities
(40,000)
(26,557)
Net (decrease)/increase in cash and cash equivalents
(350,536)
244,373
Cash and cash equivalents at beginning of year
366,660
122,287
Cash and cash equivalents at end of year
16,124
366,660
RENAISSANCE CARE (SCOTLAND) LIMITED
NOTES TO THE GROUP FINANCIAL STATEMENTS
FOR THE YEAR ENDED 30 NOVEMBER 2025
- 16 -
1
Accounting policies
Company information

Renaissance Care (Scotland) Limited (“the company”) is a private limited company domiciled and incorporated in Scotland. The registered office is Archibald Hope House, Station Road, Musselburgh, EH21 7PQ.

 

The group consists of Renaissance Care (Scotland) Limited and all of its subsidiaries.

1.1
Basis of preparation

These financial statements have been prepared in accordance with FRS 102 “The Financial Reporting Standard applicable in the UK and Republic of Ireland” (“FRS 102”) and the requirements of the Companies Act 2006.

The financial statements are prepared in sterling, which is the functional currency of the company. Monetary amounts in these financial statements are rounded to the nearest £.

The financial statements have been prepared under the historical cost convention, The principal accounting policies adopted are set out below.

1.2
Basis of consolidation

The consolidated group financial statements consist of the financial statements of the parent company Renaissance Care (Scotland) Limited together with all entities controlled by the parent company (its subsidiaries) and the group’s share of its interests in joint ventures and associates.

 

All financial statements are made up to 30 November 2025. Where necessary, adjustments are made to the financial statements of subsidiaries to bring the accounting policies used into line with those used by other members of the group.

 

All intra-group transactions, balances and unrealised gains on transactions between group companies are eliminated on consolidation. Unrealised losses are also eliminated unless the transaction provides evidence of an impairment of the asset transferred.

Entities in which the group holds an interest and which are jointly controlled by the group and one or more other venturers under a contractual arrangement are treated as joint ventures. Entities other than subsidiary undertakings or joint ventures, in which the group has a participating interest and over whose operating and financial policies the group exercises a significant influence, are treated as associates.

Investments in joint ventures and associates are carried in the group statement of financial position at cost plus post-acquisition changes in the group’s share of the net assets of the entity, less any impairment in value. The carrying values of investments in joint ventures and associates include acquired goodwill.

 

If the group’s share of losses in a joint venture or associate equals or exceeds its investment in the joint venture or associate, the group does not recognise further losses unless it has incurred obligations to do so or has made payments on behalf of the joint venture or associate.

 

Unrealised gains arising from transactions with joint ventures and associates are eliminated to the extent of the group’s interest in the entity.

1.3
Going concern

At the time of approving the financial statements, the directors consider that the company has adequate resources to continue in operational existence for a period of not less than 12 months. The directors have reviewed their budgets and cashflow requirements and are satisfied that the group has sufficient cash reserves and net income and consider that this is sufficient to ensure short term liquidity and longer-term financial viability of the group. As such the directors continue to adopt the going concern basis of accounting in preparing the financial statements.

RENAISSANCE CARE (SCOTLAND) LIMITED
NOTES TO THE GROUP FINANCIAL STATEMENTS (CONTINUED)
FOR THE YEAR ENDED 30 NOVEMBER 2025
1
Accounting policies
(Continued)
- 17 -
1.4
Revenue

Turnover is recognised at the fair value of the consideration received or receivable for goods and services provided in the normal course of business, and is shown net of VAT and other sales related taxes.

 

Revenue represents fee income relating to the provision of care services. Fee income comprises residential, nursing and personal care services which are recognised when the delivery of service is completed. Fees invoiced in advance are included as deferred income until the service is completed.

1.5
Intangible fixed assets - goodwill

Goodwill represents the excess of the cost of acquisition of a business over the fair value of net assets acquired. It is initially recognised as an asset at cost and is subsequently measured at cost less accumulated amortisation and accumulated impairment losses. Inversely to this, Negative Goodwill represents the difference between the fair value of net assets acquired in relation to the amount paid. Goodwill is considered to have a finite useful life and is amortised on a systematic basis over its expected life, which is 10 years.

 

For the purposes of impairment testing, goodwill is allocated to the cash-generating units expected to benefit from the acquisition. Cash-generating units to which goodwill has been allocated are tested for impairment at least annually, or more frequently when there is an indication that the unit may be impaired. If the recoverable amount of the cash-generating unit is less than the carrying amount of the unit, the impairment loss is allocated first to reduce the carrying amount of any goodwill allocated to the unit and then to the other assets of the unit pro-rata on the basis of the carrying amount of each asset in the unit.

1.6
Intangible fixed assets other than goodwill

Intangible assets acquired separately from a business are recognised at cost and are subsequently measured at cost less accumulated amortisation and accumulated impairment losses.

 

Intangible assets acquired on business combinations are recognised separately from goodwill at the acquisition date where it is probable that the expected future economic benefits that are attributable to the asset will flow to the entity and the fair value of the asset can be measured reliably; the intangible asset arises from contractual or other legal rights; and the intangible asset is separable from the entity.

Amortisation is recognised so as to write off the cost or valuation of assets less their residual values over their useful lives on the following bases:

Patents & licences
10% straight line
1.7
Tangible fixed assets

Tangible fixed assets are initially measured at cost and subsequently measured at cost or valuation, net of depreciation and any impairment losses.

Depreciation is recognised so as to write off the cost or valuation of assets less their residual values over their useful lives on the following bases:

Land and buildings heritable
Nil
Leasehold improvements
20% straight line
Fixtures, fittings & equipment
20% reducing balance
Computer equipment
25% straight line
Motor vehicles
25% straight line

The gain or loss arising on the disposal of an asset is determined as the difference between the sale proceeds and the carrying value of the asset, and is recognised in the income statement.

RENAISSANCE CARE (SCOTLAND) LIMITED
NOTES TO THE GROUP FINANCIAL STATEMENTS (CONTINUED)
FOR THE YEAR ENDED 30 NOVEMBER 2025
1
Accounting policies
(Continued)
- 18 -
1.8
Fixed asset investments

Equity investments are measured at fair value through profit or loss, except for those equity investments that are not publicly traded and whose fair value cannot otherwise be measured reliably, which are recognised at cost less impairment until a reliable measure of fair value becomes available.

 

In the parent company financial statements, investments in subsidiaries, associates and jointly controlled entities are initially measured at cost and subsequently measured at cost less any accumulated impairment losses.

A subsidiary is an entity controlled by the group. Control is the power to govern the financial and operating policies of the entity so as to obtain benefits from its activities.

1.9
Impairment of fixed assets

At each reporting period end date, the group reviews the carrying amounts of its tangible and intangible assets to determine whether there is any indication that those assets have suffered an impairment loss. If any such indication exists, the recoverable amount of the asset is estimated in order to determine the extent of the impairment loss (if any). Where it is not possible to estimate the recoverable amount of an individual asset, the company estimates the recoverable amount of the cash-generating unit to which the asset belongs.

 

The carrying amount of the investments accounted for using the equity method is tested for impairment as a single asset. Any goodwill included in the carrying amount of the investment is not tested separately for impairment.

Recoverable amount is the higher of fair value less costs to sell and value in use. In assessing value in use, the estimated future cash flows are discounted to their present value using a pre-tax discount rate that reflects current market assessments of the time value of money and the risks specific to the asset for which the estimates of future cash flows have not been adjusted.

 

If the recoverable amount of an asset (or cash-generating unit) is estimated to be less than its carrying amount, the carrying amount of the asset (or cash-generating unit) is reduced to its recoverable amount. An impairment loss is recognised immediately in profit or loss, unless the relevant asset is carried at a revalued amount, in which case the impairment loss is treated as a revaluation decrease.

Recognised impairment losses are reversed if, and only if, the reasons for the impairment loss have ceased to apply. Where an impairment loss subsequently reverses, the carrying amount of the asset (or cash-generating unit) is increased to the revised estimate of its recoverable amount, but so that the increased carrying amount does not exceed the carrying amount that would have been determined had no impairment loss been recognised for the asset (or cash-generating unit) in prior years. A reversal of an impairment loss is recognised immediately in profit or loss, unless the relevant asset is carried at a revalued amount, in which case the reversal of the impairment loss is treated as a revaluation increase.

1.10
Cash and cash equivalents

Cash and cash equivalents are basic financial assets and include cash in hand, deposits held at call with banks, other short-term liquid investments with original maturities of three months or less, and bank overdrafts. Bank overdrafts are shown within borrowings in current liabilities.

RENAISSANCE CARE (SCOTLAND) LIMITED
NOTES TO THE GROUP FINANCIAL STATEMENTS (CONTINUED)
FOR THE YEAR ENDED 30 NOVEMBER 2025
1
Accounting policies
(Continued)
- 19 -
1.11
Financial instruments

The group has elected to apply the provisions of Section 11 ‘Basic Financial Instruments’ and Section 12 ‘Other Financial Instruments Issues’ of FRS 102 to all of its financial instruments.

 

Financial instruments are recognised in the group's statement of financial position when the group becomes party to the contractual provisions of the instrument.

 

Financial assets and liabilities are offset and the net amounts presented in the financial statements when there is a legally enforceable right to set off the recognised amounts and there is an intention to settle on a net basis or to realise the asset and settle the liability simultaneously.

Basic financial assets

Basic financial assets, which include debtors and cash and bank balances, are initially measured at transaction price including transaction costs and are subsequently carried at amortised cost using the effective interest method unless the arrangement constitutes a financing transaction, where the transaction is measured at the present value of the future receipts discounted at a market rate of interest. Financial assets classified as receivable within one year are not amortised.

Other financial assets

Other financial assets, including investments in equity instruments which are not subsidiaries, associates or joint ventures, are initially measured at fair value, which is normally the transaction price. Such assets are subsequently carried at fair value and the changes in fair value are recognised in profit or loss, except that investments in equity instruments that are not publicly traded and whose fair values cannot be measured reliably are measured at cost less impairment.

Derecognition of financial assets

Financial assets are derecognised only when the contractual rights to the cash flows from the asset expire or are settled, or when the group transfers the financial asset and substantially all the risks and rewards of ownership to another entity, or if some significant risks and rewards of ownership are retained but control of the asset has transferred to another party that is able to sell the asset in its entirety to an unrelated third party.

Classification of financial liabilities

Financial liabilities and equity instruments are classified according to the substance of the contractual arrangements entered into. An equity instrument is any contract that evidences a residual interest in the assets of the group after deducting all of its liabilities.

Basic financial liabilities

Basic financial liabilities, including creditors, bank loans, loans from fellow group companies and preference shares that are classified as debt, are initially recognised at transaction price unless the arrangement constitutes a financing transaction, where the debt instrument is measured at the present value of the future payments discounted at a market rate of interest. Financial liabilities classified as payable within one year are not amortised.

 

Debt instruments are subsequently carried at amortised cost, using the effective interest rate method.

 

Trade creditors are obligations to pay for goods or services that have been acquired in the ordinary course of business from suppliers. Amounts payable are classified as current liabilities if payment is due within one year or less. If not, they are presented as non-current liabilities. Trade creditors are recognised initially at transaction price and subsequently measured at amortised cost using the effective interest method.

Derecognition of financial liabilities

Financial liabilities are derecognised when the group's contractual obligations expire or are discharged or cancelled.

RENAISSANCE CARE (SCOTLAND) LIMITED
NOTES TO THE GROUP FINANCIAL STATEMENTS (CONTINUED)
FOR THE YEAR ENDED 30 NOVEMBER 2025
1
Accounting policies
(Continued)
- 20 -
1.12
Equity instruments

Equity instruments issued by the group are recorded at the proceeds received, net of transaction costs. Dividends payable on equity instruments are recognised as liabilities once they are no longer at the discretion of the group.

1.13
Taxation

The tax expense represents the sum of the tax currently payable and deferred tax.

Current tax

The tax currently payable is based on taxable profit for the year. Taxable profit differs from net profit as reported in the income statement because it excludes items of income or expense that are taxable or deductible in other years and it further excludes items that are never taxable or deductible. The group’s liability for current tax is calculated using tax rates that have been enacted or substantively enacted by the reporting end date.

Deferred tax

Deferred tax liabilities are generally recognised for all timing differences and deferred tax assets are recognised to the extent that it is probable that they will be recovered against the reversal of deferred tax liabilities or other future taxable profits. Such assets and liabilities are not recognised if the timing difference arises from goodwill or from the initial recognition of other assets and liabilities in a transaction that affects neither the tax profit nor the accounting profit.

The carrying amount of deferred tax assets is reviewed at each reporting end date and reduced to the extent that it is no longer probable that sufficient taxable profits will be available to allow all or part of the asset to be recovered. Deferred tax is calculated at the tax rates that are expected to apply in the period when the liability is settled or the asset is realised. Deferred tax is charged or credited in the income statement, except when it relates to items charged or credited directly to equity, in which case the deferred tax is also dealt with in equity. Deferred tax assets and liabilities are offset if, and only if, there is a legally enforceable right to offset current tax assets and liabilities and the deferred tax assets and liabilities relate to taxes levied by the same tax authority.

1.14
Employee benefits

The costs of short-term employee benefits are recognised as a liability and an expense, unless those costs are required to be recognised as part of the cost of stock or fixed assets.

 

The cost of any unused holiday entitlement is recognised in the period in which the employee’s services are received.

1.15
Retirement benefits

Payments to defined contribution retirement benefit schemes are charged as an expense as they fall due.

1.16
Share-based payments

Equity-settled share-based payments are measured at fair value at the date of grant by reference to the fair value of the equity instruments granted using the Black–Scholes model. The fair value determined at the grant date is expensed on a straight-line basis over the vesting period, based on the estimate of shares that will eventually vest. A corresponding adjustment is made to equity.

 

RENAISSANCE CARE (SCOTLAND) LIMITED
NOTES TO THE GROUP FINANCIAL STATEMENTS (CONTINUED)
FOR THE YEAR ENDED 30 NOVEMBER 2025
1
Accounting policies
(Continued)
- 21 -
1.17
Leases
As lessee

Leases are classified as finance leases whenever the terms of the lease transfer substantially all the risks and rewards of ownership to the lessees. All other leases are classified as operating leases.

 

Assets held under finance leases are recognised as assets at the lower of the assets fair value at the date of inception and the present value of the minimum lease payments. The related liability is included in the statement of financial position as a finance lease obligation. Lease payments are treated as consisting of capital and interest elements. The interest is charged to profit or loss so as to produce a constant periodic rate of interest on the remaining balance of the liability.

Rentals payable under operating leases, including any lease incentives received, are charged to profit or loss on a straight line basis over the term of the relevant lease except where another more systematic basis is more representative of the time pattern in which economic benefits from the leased asset are consumed.

2
Turnover and other revenue
2025
2024
£
£
Turnover analysed by class of business
Sale of goods and services
52,518,142
45,846,412
2025
2024
£
£
Other revenue
Interest income
15,179
4,572
3
Operating profit
2025
2024
£
£
Operating profit for the year is stated after charging:
Depreciation of tangible fixed assets
981,218
811,904
Loss on disposal of tangible fixed assets
109,801
4,873
Amortisation of intangible assets
186,113
1,850
Operating lease charges
5,629,971
5,424,191
4
Auditor's remuneration
2025
2024
Fees payable to the company's auditor and associates:
£
£
For audit services
Audit of the financial statements of the group and company
8,797
7,195
Audit of the financial statements of the company's subsidiaries
74,936
46,962
83,733
54,157
RENAISSANCE CARE (SCOTLAND) LIMITED
NOTES TO THE GROUP FINANCIAL STATEMENTS (CONTINUED)
FOR THE YEAR ENDED 30 NOVEMBER 2025
- 22 -
5
Employees

The average monthly number of persons (including directors) employed by the group and company during the year was:

Group
Company
2025
2024
2025
2024
Number
Number
Number
Number
Administrative staff
30
30
-
-
Management staff
39
39
-
-
Number of nursing/care staff
1,275
1,399
-
-
Directors
12
11
8
7
Total
1,356
1,479
8
7

Their aggregate remuneration comprised:

Group
Company
2025
2024
2025
2024
£
£
£
£
Wages and salaries
33,371,720
28,670,215
-
0
-
0
Pension costs
653,333
596,400
-
0
-
0
34,025,053
29,266,615
-
0
-
0
6
Interest receivable and similar income
2025
2024
£
£
Interest income
Interest on bank deposits
15,179
4,572
2025
2024
Investment income includes the following:
£
£
Interest on financial assets not measured at fair value through profit or loss
15,179
4,572
7
Interest payable and similar expenses
2025
2024
£
£
Interest on financial liabilities measured at amortised cost:
Interest on bank overdrafts and loans
80,039
2,853
Other finance costs:
Interest on finance leases and hire purchase contracts
714
773
Total finance costs
80,753
3,626
RENAISSANCE CARE (SCOTLAND) LIMITED
NOTES TO THE GROUP FINANCIAL STATEMENTS (CONTINUED)
FOR THE YEAR ENDED 30 NOVEMBER 2025
- 23 -
8
Taxation
2025
2024
£
£
Current tax
UK corporation tax on profits for the current period
297,099
265,166
Adjustments in respect of prior periods
21,427
(5,027)
Total current tax
318,526
260,139
Deferred tax
Origination and reversal of timing differences
257,559
26,046
Total tax charge
576,085
286,185

The actual charge for the year can be reconciled to the expected charge for the year based on the profit or loss and the standard rate of tax as follows:

2025
2024
£
£
Profit before taxation
2,158,494
1,981,599
Expected tax charge based on the standard rate of corporation tax in the UK of 25.00% (2024: 25.00%)
539,624
495,400
Tax effect of expenses that are not deductible in determining taxable profit
52,037
14,122
Unutilised tax losses carried forward
(7,015)
-
0
Adjustments in respect of prior years
21,427
(5,027)
Effect of change in corporation tax rate
-
(272)
Group relief
(140,813)
(92,989)
Permanent capital allowances in excess of depreciation
(174,184)
(151,095)
Deferred tax adjustments in respect of prior years
257,559
26,046
Loss on sale of fixed assets
27,450
-
0
Taxation charge
576,085
286,185
9
Dividends
2025
2024
Recognised as distributions to equity holders:
£
£
Final paid
40,000
26,820
RENAISSANCE CARE (SCOTLAND) LIMITED
NOTES TO THE GROUP FINANCIAL STATEMENTS (CONTINUED)
FOR THE YEAR ENDED 30 NOVEMBER 2025
- 24 -
10
Intangible fixed assets
Group
Goodwill
Patents & licences
Total
£
£
£
Cost
At 1 December 2024
1,321,221
53,936
1,375,157
Additions
482,282
1,686
483,968
Disposals
-
0
(8,340)
(8,340)
At 30 November 2025
1,803,503
47,282
1,850,785
Amortisation and impairment
At 1 December 2024
-
0
9,040
9,040
Amortisation charged for the year
180,350
5,763
186,113
At 30 November 2025
180,350
14,803
195,153
Carrying amount
At 30 November 2025
1,623,153
32,479
1,655,632
At 30 November 2024
1,321,221
44,896
1,366,117
Company
Patents & licences
£
Cost
At 1 December 2024 and 30 November 2025
17,700
Amortisation and impairment
At 1 December 2024
9,040
Amortisation charged for the year
1,770
At 30 November 2025
10,810
Carrying amount
At 30 November 2025
6,890
At 30 November 2024
8,660
RENAISSANCE CARE (SCOTLAND) LIMITED
NOTES TO THE GROUP FINANCIAL STATEMENTS (CONTINUED)
FOR THE YEAR ENDED 30 NOVEMBER 2025
- 25 -
11
Tangible fixed assets
Group
Land and buildings heritable
Leasehold improvements
Fixtures, fittings & equipment
Computer equipment
Motor vehicles
Total
£
£
£
£
£
£
Cost or valuation
At 1 December 2024
674,140
180,385
5,603,300
439,158
246,627
7,143,610
Additions
196,652
26,481
1,623,884
95,654
27,003
1,969,674
Business combinations
-
0
-
0
31,170
-
0
50,099
81,269
Disposals
(19,425)
(10,862)
(572,649)
(10,780)
(19,500)
(633,216)
Transfers
-
0
(1,937)
-
0
1,937
-
0
-
0
At 30 November 2025
851,367
194,067
6,685,705
525,969
304,229
8,561,337
Depreciation and impairment
At 1 December 2024
386,053
2,766
2,722,480
237,527
185,648
3,534,474
Depreciation charged in the year
70,946
10,721
707,538
103,311
88,702
981,218
Eliminated in respect of disposals
(17,865)
-
0
(484,170)
(6,349)
(15,031)
(523,415)
At 30 November 2025
439,134
13,487
2,945,848
334,489
259,319
3,992,277
Carrying amount
At 30 November 2025
412,233
180,580
3,739,857
191,480
44,910
4,569,060
At 30 November 2024
288,087
177,619
2,880,820
201,631
60,979
3,609,136
Company
Fixtures, fittings & equipment
Computer equipment
Total
£
£
£
Cost or valuation
At 1 December 2024
14,576
244
14,820
Disposals
(6,894)
-
0
(6,894)
At 30 November 2025
7,682
244
7,926
Depreciation and impairment
At 1 December 2024
10,866
139
11,005
Depreciation charged in the year
1,240
61
1,301
Eliminated in respect of disposals
(6,894)
-
0
(6,894)
At 30 November 2025
5,212
200
5,412
Carrying amount
At 30 November 2025
2,470
44
2,514
At 30 November 2024
3,710
105
3,815
RENAISSANCE CARE (SCOTLAND) LIMITED
NOTES TO THE GROUP FINANCIAL STATEMENTS (CONTINUED)
FOR THE YEAR ENDED 30 NOVEMBER 2025
11
Tangible fixed assets
(Continued)
- 26 -

Included within tangible fixed assets are assets held under finance leases or hire purchase contracts, as follows:

Group
Company
2025
2024
2025
2024
£
£
£
£
Motor vehicles
-
0
8,551
-
0
-
0
2025
2024
£
£
Group
Cost
819,348
642,121
Accumulated depreciation
(436,439)
(383,358)
Carrying value
382,909
258,763
12
Fixed asset investments
Group
Company
2025
2024
2025
2024
Notes
£
£
£
£
Investments in subsidiaries
13
-
0
-
0
1,875,495
2,001,343
Movements in fixed asset investments
Company
Shares in subsidiaries
£
Cost or valuation
At 1 December 2024
2,001,343
Valuation changes
(125,848)
At 30 November 2025
1,875,495
Carrying amount
At 30 November 2025
1,875,495
At 30 November 2024
2,001,343
13
Subsidiaries

Details of the company's subsidiaries at 30 November 2025 are as follows:

RENAISSANCE CARE (SCOTLAND) LIMITED
NOTES TO THE GROUP FINANCIAL STATEMENTS (CONTINUED)
FOR THE YEAR ENDED 30 NOVEMBER 2025
13
Subsidiaries
(Continued)
- 27 -
Name of undertaking
Registered office
Class of
% Held
shares held
Direct
Indirect
Renaissance Care (No 1) Limited
Ordinary Shares
0
100.00
Renaissance Care (No 2) Limited
Ordinary Shares
100.00
-
Renaissance Care (No 3) Limited
Ordinary Shares
0
100.00
Renaissance Care (No 4) Limited
Ordinary Shares
0
100.00
Renaissance Care (No 5) Limited
Ordinary Shares
100.00
-
Renaissance Care (No 6) Ltd
Ordinary Shares
100.00
-
Renaissance Care (No 7) Limited
Ordinary Shares
100.00
-
Renaissance Care (No 8) Limited
Ordinary Shares
100.00
-
Renaissance Care (No 9) Limited
Ordinary Shares
100.00
-
Cura Services (Scotland) Limited
Ordinary Shares
100.00
-
Renaissance Care (No 10) Ltd
Ordinary Shares
100.00
-
Renaissance Care (UK) Ltd
Ordinary Shares
100.00
-
Duncare Limited
Ordinary Shares
0
100.00
Holistic Elderly Care Limited
Ordinary Shares
100.00
-

The registered office of all subsidiaries is Archibald Hope House, Station Road, Musselburgh, Scotland, EH21 7PQ.

 

14
Debtors
Group
Company
2025
2024
2025
2024
Amounts falling due within one year:
£
£
£
£
Trade debtors
3,033,310
2,743,772
-
0
-
0
Amounts owed by group undertakings
7,173,506
5,510,587
5,230,588
4,383,522
Other debtors
348,321
467,480
-
0
-
0
Prepayments and accrued income
528,850
889,930
496
499
11,083,987
9,611,769
5,231,084
4,384,021
15
Creditors: amounts falling due within one year
Group
Company
2025
2024
2025
2024
Notes
£
£
£
£
Obligations under finance leases
18
-
0
4,505
-
0
-
0
Trade creditors
1,566,654
1,407,398
-
0
-
0
Amounts owed to group undertakings
7,102,096
5,367,610
6,798,340
5,096,493
Corporation tax payable
195,410
173,803
-
0
-
0
Other taxation and social security
1,411,804
1,573,110
-
0
-
0
Other creditors
2,345,298
2,141,226
-
0
-
0
Accruals and deferred income
1,904,346
2,956,024
8,267
1,288,397
14,525,608
13,623,676
6,806,607
6,384,890
RENAISSANCE CARE (SCOTLAND) LIMITED
NOTES TO THE GROUP FINANCIAL STATEMENTS (CONTINUED)
FOR THE YEAR ENDED 30 NOVEMBER 2025
15
Creditors: amounts falling due within one year
(Continued)
- 28 -

Landlords of leased properties hold standard securities over their respective properties and floating charges over the undertaking, property and assets of the individual legal entities whose business operated from their homes. No rental guarantees have been granted by Renaissance Care (UK) Limited, Renaissance Care (Scotland) Limited or Dow Investments PLC.

16
Creditors: amounts falling due after more than one year
Group
Company
2025
2024
2025
2024
Notes
£
£
£
£
Bank loans and overdrafts
17
906,000
-
0
-
0
-
0
Obligations under finance leases
18
-
0
17,888
-
0
-
0
906,000
17,888
-
-
17
Loans and overdrafts
Group
Company
2025
2024
2025
2024
£
£
£
£
Bank loans
906,000
-
0
-
0
-
0
Payable after one year
906,000
-
0
-
0
-
0

The Royal Bank of Scotland Plc hold a floating charge dated 6 March 2017 over all property and undertakings of the Holistic Elderly Care Limited.

18
Finance lease obligations
Group
Company
2025
2024
2025
2024
Amounts due:
£
£
£
£
Current liabilities
-
0
4,505
-
0
-
0
Non-current liabilities
-
0
17,888
-
0
-
0
-
22,393
-
-
RENAISSANCE CARE (SCOTLAND) LIMITED
NOTES TO THE GROUP FINANCIAL STATEMENTS (CONTINUED)
FOR THE YEAR ENDED 30 NOVEMBER 2025
18
Finance lease obligations
(Continued)
- 29 -
Group
Company
2025
2024
2025
2024
£
£
£
£
Future minimum lease payments due under finance leases:
Within one year
-
0
4,505
-
0
-
0
In two to five years
-
0
17,888
-
0
-
0
-
22,393
-
-

Finance lease payments represent rentals payable by the company or group for certain items of plant and machinery. Leases include purchase options at the end of the lease period, and no restrictions are placed on the use of the assets. The average lease term is 5 years. All leases are on a fixed repayment basis and no arrangements have been entered into for contingent rental payments.

19
Deferred taxation

The following are the major deferred tax liabilities and assets recognised by the group and company, and movements thereon:

Liabilities
Liabilities
2025
2024
Group
£
£
Accelerated capital allowances
858,056
598,652
Liabilities
Liabilities
2025
2024
Company
£
£
Accelerated capital allowances
629
954
Group
Company
2025
2025
Movements in the year:
£
£
Liability at 1 December 2024
598,652
954
Charge/(credit) to profit or loss
259,404
(325)
Liability at 30 November 2025
858,056
629
RENAISSANCE CARE (SCOTLAND) LIMITED
NOTES TO THE GROUP FINANCIAL STATEMENTS (CONTINUED)
FOR THE YEAR ENDED 30 NOVEMBER 2025
- 30 -
20
Retirement benefit schemes
2025
2024
Defined contribution schemes
£
£
Charge to profit or loss in respect of defined contribution schemes
653,333
596,400

A defined contribution pension scheme is operated for all qualifying employees. The assets of the scheme are held separately from those of the group in an independently administered fund.

21
Share-based payment transactions
Group and company
Number of share options
Weighted average exercise price
2025
2024
2025
2024
Number
Number
£
£
Outstanding at 1 December 2024 and 30 November 2025
2,924
2,924
1.00
1.00
Exercisable at 30 November 2025
2,924
2,924
1.00
1.00

The options outstanding at 30 November 2025 had an exercise price of £1, and a remaining contractual life of 2.83 years.

 

The weighted average fair value of options granted in the year was determined using the Black-Scholes option pricing model. The Black-Scholes model is considered to apply the most appropriate valuation method due to the relatively short contractual lives of the options and the requirement to exercise within a short period after the employee becomes entitled to the shares (the “vesting date”).

 

The expected life used in the model has been adjusted, based on management’s best estimate, for the effect of non-transferability, exercise restrictions, and behavioural considerations.

 

Non-vesting conditions and market conditions are taken into account when estimating the fair value of the option at grant date. Service conditions and non-market performance conditions are taken into account by adjusting the number of options expected to vest at each reporting date.

 

22
Share capital
Group and company
2025
2024
2025
2024
Ordinary share capital
Number
Number
£
£
Issued and fully paid
Ordinary 'A' shares of £1 each
37,500
37,500
37,500
37,500
Ordinary 'B' shares of £1 each
12,500
12,500
12,500
12,500
Ordinary 'C' shares of £1 each
2,632
2,632
2,632
2,632
52,632
52,632
52,632
52,632
RENAISSANCE CARE (SCOTLAND) LIMITED
NOTES TO THE GROUP FINANCIAL STATEMENTS (CONTINUED)
FOR THE YEAR ENDED 30 NOVEMBER 2025
22
Share capital
(Continued)
- 31 -

The Ordinary A shares, Ordinary B and Ordinary C shares rank equally with regard to voting and participation, with regards dividends the shares will rank pari passu except that the directors may at any time resolve to declare a dividend on one or more classes of shares.

23
Share premium account
Group
Company
2025
2024
2025
2024
£
£
£
£
At the beginning of the year
263
-
0
263
-
0
Issue of new shares
-
263
-
263
At the end of the year
263
263
263
263
24
Other reserves
2025
2024
Group and company
£
£
At the beginning and end of the year
449
449

The other reserve represents an equity-settled employee benefits reserve relating to share options granted by the company to a director.

25
Profit and loss reserves
Group
Company
2025
2024
2025
2024
£
£
£
£
At the beginning of the year
2,458,955
790,361
325,311
365,983
Profit/(loss) for the year
1,582,409
1,695,414
(13,784)
(13,852)
Dividends
(40,000)
(26,820)
(40,000)
(26,820)
At the end of the year
4,001,364
2,458,955
271,527
325,311
26
Financial commitments, guarantees and contingent liabilities

There is an unlimited intercompany cross guarantee in favour of Cynergy Bank Limited from Dow Investments PLC, Renaissance Care (Scotland) Limited, SCHI Ltd, Renaissance Care (No 2) Limited, Renaissance Care (No 5) Limited, Renaissance Care (No 6) Ltd and Renaissance Care (No 9) Limited.

RENAISSANCE CARE (SCOTLAND) LIMITED
NOTES TO THE GROUP FINANCIAL STATEMENTS (CONTINUED)
FOR THE YEAR ENDED 30 NOVEMBER 2025
- 32 -
27
Related party transactions
Remuneration of key management personnel

The remuneration of key management personnel is as follows.

2025
2024
£
£
Aggregate compensation
624,258
622,803
Transactions with related parties

Group


Transactions between group companies, which are related parties, have been eliminated on consolidation and are not disclosed in this note.

During the year the group entered into the following transactions with related parties:

Purchases
Purchases
2025
2024
£
£
Group
Entities over which the group has control, joint control or significant influence
848,220
675,595

Company


The following amounts were outstanding at the reporting end date:

Amounts due to related parties
2025
2024
£
£
Company
Entities with control, joint control or significant influence over the company
3,361,600
3,200,794
28
Controlling party

The directors consider the ultimate controlling party throughout the current year to be Dow Investments PLC, a company incorporated in Scotland, as a result of its controlling interest in Renaissance Care (Scotland) Limited.

 

Dow Investments PLC is controlled by Mr R D Kilgour, director.

 

The accounts of Dow Investments PLC are available to the public via Companies House. The registered office of this company is Archibald Hope House, Station Road, Musselburgh, Scotland, EH21 7PQ. The company heads its largest group and smallest group in which the results of this company are included.

 

RENAISSANCE CARE (SCOTLAND) LIMITED
NOTES TO THE GROUP FINANCIAL STATEMENTS (CONTINUED)
FOR THE YEAR ENDED 30 NOVEMBER 2025
- 33 -
29
Cash generated from group operations
2025
2024
£
£
Profit after taxation
1,582,409
1,695,414
Adjustments for:
Taxation charged
576,085
286,185
Finance costs
80,753
3,626
Investment income
(15,179)
(4,572)
Loss on disposal of tangible fixed assets
109,801
4,873
Amortisation and impairment of intangible assets
186,113
1,850
Depreciation and impairment of tangible fixed assets
981,218
811,904
Movements in working capital:
Decrease in stocks
-
3,231
Increase in debtors
(1,472,218)
(356,281)
Increase in creditors
884,830
1,620,722
Cash generated from operations
2,913,812
4,066,952
30
Cash (absorbed by)/generated from operations - company
2025
2024
£
£
Loss after taxation
(13,784)
(13,852)
Adjustments for:
Taxation credited
(325)
(247)
Finance costs
2,292
2,500
Investment income
(305)
-
0
Amortisation and impairment of intangible assets
1,770
1,850
Depreciation and impairment of tangible fixed assets
1,301
989
Movements in working capital:
Increase in debtors
(847,063)
(814,095)
Increase in creditors
421,717
2,377,341
Cash (absorbed by)/generated from operations
(434,397)
1,554,486
RENAISSANCE CARE (SCOTLAND) LIMITED
NOTES TO THE GROUP FINANCIAL STATEMENTS (CONTINUED)
FOR THE YEAR ENDED 30 NOVEMBER 2025
- 34 -
31
Analysis of changes in net funds - group
1 December 2024
Cash flows
30 November 2025
£
£
£
Cash at bank and in hand
2,165,493
870,200
3,035,693
Borrowings excluding overdrafts
-
(906,000)
(906,000)
Obligations under finance leases
(22,393)
22,393
-
2,143,100
(13,407)
2,129,693
32
Analysis of changes in net funds - company
1 December 2024
Cash flows
30 November 2025
£
£
£
Cash at bank and in hand
366,660
(350,536)
16,124
2025-11-302024-12-01falsefalseCCH SoftwareCCH Accounts Production 2026.100Mr R D KilgourMr R D HarperMrs A NeilsonMrs L BarnettMrs Y RichardsonMr M H ReidMr L M BainMs K FeenanfalseSC190022bus:Consolidated2024-12-012025-11-30SC1900222024-12-012025-11-30SC190022bus:Director12024-12-012025-11-30SC190022bus:Director22024-12-012025-11-30SC190022bus:Director32024-12-012025-11-30SC190022bus:Director42024-12-012025-11-30SC190022bus:Director52024-12-012025-11-30SC190022bus:Director62024-12-012025-11-30SC190022bus:Director72024-12-012025-11-30SC190022bus:Director82024-12-012025-11-30SC190022bus:RegisteredOffice2024-12-012025-11-30SC190022bus:Agent12024-12-012025-11-30SC190022core:CapitalRedemptionReserve2023-11-30SC190022core:OtherMiscellaneousReserve2023-11-30SC190022core:ShareCapitalbus:Consolidated2025-11-30SC190022core:ShareCapitalbus:Consolidated2024-11-30SC190022core:SharePremiumbus:Consolidated2025-11-30SC190022core:SharePremiumbus:Consolidated2024-11-30SC190022core:OtherMiscellaneousReservebus:Consolidated2025-11-30SC190022core:OtherMiscellaneousReservebus:Consolidated2024-11-30SC190022core:RetainedEarningsAccumulatedLossesbus:Consolidated2025-11-30SC190022core:RetainedEarningsAccumulatedLossesbus:Consolidated2024-11-30SC190022bus:Consolidated2025-11-30SC190022bus:Consolidated2024-11-30SC190022core:ShareCapital2025-11-30SC190022core:ShareCapital2024-11-30SC190022core:SharePremium2025-11-30SC190022core:SharePremium2024-11-30SC190022core:OtherMiscellaneousReserve2025-11-30SC190022core:OtherMiscellaneousReserve2024-11-30SC190022core:RetainedEarningsAccumulatedLosses2025-11-30SC190022core:RetainedEarningsAccumulatedLosses2024-11-30SC1900222025-11-30SC1900222024-11-30SC190022core:ShareCapitalbus:Consolidated2023-11-30SC190022core:SharePremiumbus:Consolidated2023-11-30SC1900222023-11-30SC190022core:ShareCapital2023-11-30SC190022core:SharePremium2023-11-30SC190022core:RetainedEarningsAccumulatedLosses2023-11-30SC190022core:SharePremiumbus:Consolidated2024-11-30SC190022core:SharePremium2024-11-30SC190022bus:Consolidated2023-12-012024-11-30SC1900222023-12-012024-11-30SC190022core:Goodwillbus:Consolidated2025-11-30SC190022core:Goodwillbus:Consolidated2024-11-30SC190022core:IntangibleAssetsOtherThanGoodwillbus:Consolidated2025-11-30SC190022core:IntangibleAssetsOtherThanGoodwillbus:Consolidated2024-11-30SC190022core:PatentsTrademarksLicencesConcessionsSimilarbus:Consolidated2025-11-30SC190022core:PatentsTrademarksLicencesConcessionsSimilarbus:Consolidated2024-11-30SC190022core:PatentsTrademarksLicencesConcessionsSimilar2025-11-30SC190022core:PatentsTrademarksLicencesConcessionsSimilar2024-11-30SC190022core:LandBuildingscore:OwnedOrFreeholdAssetsbus:Consolidated2025-11-30SC190022core:LeaseholdImprovementsbus:Consolidated2025-11-30SC190022core:FurnitureFittingsbus:Consolidated2025-11-30SC190022core:ComputerEquipmentbus:Consolidated2025-11-30SC190022core:MotorVehiclesbus:Consolidated2025-11-30SC190022core:LandBuildingscore:OwnedOrFreeholdAssetsbus:Consolidated2024-11-30SC190022core:LeaseholdImprovementsbus:Consolidated2024-11-30SC190022core:FurnitureFittingsbus:Consolidated2024-11-30SC190022core:ComputerEquipmentbus:Consolidated2024-11-30SC190022core:MotorVehiclesbus:Consolidated2024-11-30SC190022core:FurnitureFittings2025-11-30SC190022core:ComputerEquipment2025-11-30SC190022core:FurnitureFittings2024-11-30SC190022core:ComputerEquipment2024-11-30SC190022core:CurrentFinancialInstrumentscore:WithinOneYearbus:Consolidated2025-11-30SC190022core:CurrentFinancialInstrumentsbus:Consolidated2024-11-30SC190022core:ShareCapitalbus:Consolidated2023-12-012024-11-30SC190022core:SharePremiumbus:Consolidated2023-12-012024-11-30SC190022core:ShareCapital2023-12-012024-11-30SC190022core:SharePremium2023-12-012024-11-30SC190022bus:Consolidated2023-11-30SC190022core:Goodwill2024-12-012025-11-30SC190022core:IntangibleAssetsOtherThanGoodwill2024-12-012025-11-30SC190022core:PatentsTrademarksLicencesConcessionsSimilar2024-12-012025-11-30SC190022core:LandBuildingscore:OwnedOrFreeholdAssets2024-12-012025-11-30SC190022core:LeaseholdImprovements2024-12-012025-11-30SC190022core:FurnitureFittings2024-12-012025-11-30SC190022core:ComputerEquipment2024-12-012025-11-30SC190022core:MotorVehicles2024-12-012025-11-30SC190022core:UKTaxbus:Consolidated2024-12-012025-11-30SC190022core:UKTaxbus:Consolidated2023-12-012024-11-30SC190022bus:Consolidated12024-12-012025-11-30SC190022bus:Consolidated12023-12-012024-11-30SC190022core:Goodwillbus:Consolidated2024-11-30SC190022core:PatentsTrademarksLicencesConcessionsSimilarbus:Consolidated2024-11-30SC190022bus:Consolidated2024-11-30SC190022core:PatentsTrademarksLicencesConcessionsSimilar2024-11-30SC190022core:Goodwillcore:ExternallyAcquiredIntangibleAssetsbus:Consolidated2024-12-012025-11-30SC190022core:PatentsTrademarksLicencesConcessionsSimilarcore:ExternallyAcquiredIntangibleAssetsbus:Consolidated2024-12-012025-11-30SC190022core:ExternallyAcquiredIntangibleAssetsbus:Consolidated2024-12-012025-11-30SC190022core:Goodwillbus:Consolidated2024-12-012025-11-30SC190022core:PatentsTrademarksLicencesConcessionsSimilarbus:Consolidated2024-12-012025-11-30SC190022core:LandBuildingscore:OwnedOrFreeholdAssetsbus:Consolidated2024-11-30SC190022core:LeaseholdImprovementsbus:Consolidated2024-11-30SC190022core:FurnitureFittingsbus:Consolidated2024-11-30SC190022core:ComputerEquipmentbus:Consolidated2024-11-30SC190022core:MotorVehiclesbus:Consolidated2024-11-30SC190022core:FurnitureFittings2024-11-30SC190022core:ComputerEquipment2024-11-30SC1900222024-11-30SC190022core:LandBuildingscore:OwnedOrFreeholdAssetsbus:Consolidated2024-12-012025-11-30SC190022core:LeaseholdImprovementsbus:Consolidated2024-12-012025-11-30SC190022core:FurnitureFittingsbus:Consolidated2024-12-012025-11-30SC190022core:ComputerEquipmentbus:Consolidated2024-12-012025-11-30SC190022core:MotorVehiclesbus:Consolidated2024-12-012025-11-30SC190022core:MotorVehicles2025-11-30SC190022core:MotorVehicles2024-11-30SC190022core:Subsidiary12024-12-012025-11-30SC190022core:Subsidiary22024-12-012025-11-30SC190022core:Subsidiary32024-12-012025-11-30SC190022core:Subsidiary42024-12-012025-11-30SC190022core:Subsidiary52024-12-012025-11-30SC190022core:Subsidiary62024-12-012025-11-30SC190022core:Subsidiary72024-12-012025-11-30SC190022core:Subsidiary82024-12-012025-11-30SC190022core:Subsidiary92024-12-012025-11-30SC190022core:Subsidiary102024-12-012025-11-30SC190022core:Subsidiary112024-12-012025-11-30SC190022core:Subsidiary122024-12-012025-11-30SC190022core:Subsidiary132024-12-012025-11-30SC190022core:Subsidiary142024-12-012025-11-30SC190022core:Subsidiary112024-12-012025-11-30SC190022core:Subsidiary222024-12-012025-11-30SC190022core:Subsidiary332024-12-012025-11-30SC190022core:Subsidiary442024-12-012025-11-30SC190022core:Subsidiary552024-12-012025-11-30SC190022core:Subsidiary662024-12-012025-11-30SC190022core:Subsidiary772024-12-012025-11-30SC190022core:Subsidiary882024-12-012025-11-30SC190022core:Subsidiary992024-12-012025-11-30SC190022core:Subsidiary10102024-12-012025-11-30SC190022core:Subsidiary11112024-12-012025-11-30SC190022core:Subsidiary12122024-12-012025-11-30SC190022core:Subsidiary13132024-12-012025-11-30SC190022core:Subsidiary14142024-12-012025-11-30SC190022core:CurrentFinancialInstrumentsbus:Consolidated2025-11-30SC190022core:CurrentFinancialInstruments2025-11-30SC190022core:CurrentFinancialInstruments2024-11-30SC190022core:CurrentFinancialInstrumentsbus:Consolidated12025-11-30SC190022core:CurrentFinancialInstrumentsbus:Consolidated12024-11-30SC190022core:CurrentFinancialInstruments22025-11-30SC190022core:CurrentFinancialInstruments22024-11-30SC190022core:Non-currentFinancialInstrumentsbus:Consolidated2025-11-30SC190022core:Non-currentFinancialInstrumentsbus:Consolidated2024-11-30SC190022core:Non-currentFinancialInstruments2025-11-30SC190022core:Non-currentFinancialInstruments2024-11-30SC190022core:CurrentFinancialInstrumentscore:WithinOneYearbus:Consolidated2024-11-30SC190022core:CurrentFinancialInstrumentscore:WithinOneYear2025-11-30SC190022core:CurrentFinancialInstrumentscore:WithinOneYear2024-11-30SC190022core:Non-currentFinancialInstrumentscore:AfterOneYearbus:Consolidated2025-11-30SC190022core:Non-currentFinancialInstrumentscore:AfterOneYearbus:Consolidated2024-11-30SC190022core:Non-currentFinancialInstrumentscore:AfterOneYear2025-11-30SC190022core:Non-currentFinancialInstrumentscore:AfterOneYear2024-11-30SC190022core:WithinOneYearbus:Consolidated2025-11-30SC190022core:WithinOneYearbus:Consolidated2024-11-30SC190022core:WithinOneYear2025-11-30SC190022core:WithinOneYear2024-11-30SC190022core:BetweenTwoFiveYearsbus:Consolidated2025-11-30SC190022core:BetweenTwoFiveYearsbus:Consolidated2024-11-30SC190022core:BetweenTwoFiveYears2025-11-30SC190022core:BetweenTwoFiveYears2024-11-30SC190022bus:PrivateLimitedCompanyLtd2024-12-012025-11-30SC190022bus:FRS1022024-12-012025-11-30SC190022bus:Audited2024-12-012025-11-30SC190022bus:ConsolidatedGroupCompanyAccounts2024-12-012025-11-30SC190022bus:FullAccounts2024-12-012025-11-30xbrli:purexbrli:sharesiso4217:GBP